In 2015, a Cognitive Vitality Report released by the Alzheimers Drug Discovery Foundation stated that two multi-year treatment trials had found that epithalamin, from which epitalon is isolated, had imparted no severe adverse events in older adults, and that preclinical trials supported a favorable safety profile.35 Ten years later, a systematic review published in 2025 stated that information regarding critical issues about this peptides safety is missing.1 In terms of human trials, the best case we have in support of epitalons safety is a 2002 trial involving 162 patients in which no one in the epitalon group reported serious side effects.36 At the same time, the U.S
Its 39-amino-acid chain with the attached fatty acid moiety creates a complex three-dimensional structure that depends on precise folding for biological activity
Deltaran, an analogue of DSIP, exhibited similar effects, enhancing V3 and ADP/t in brain homogenates, mimicking the action of pure DSIP
This continues for 6 weeks, with reassessment at the midpoint
